BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nasr AO, Dillon MF, Conlon S, Downey P, Chen G, Ireland A, Leen E, Bouchier-hayes D, Walsh TN. Acid suppression increases rates of Barrett’s esophagus and esophageal injury in the presence of duodenal reflux. Surgery 2012;151:382-90. [DOI: 10.1016/j.surg.2011.08.021] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Greene CL, Worrell SG, Demeester TR. Rat Reflux Model of Esophageal Cancer and Its Implication in Human Disease. Annals of Surgery 2015;262:910-24. [DOI: 10.1097/sla.0000000000001207] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
2 Prichard DO, Byrne AM, Murphy JO, Reynolds JV, O'Sullivan J, Feighery R, Doyle B, Eldin OS, Finn SP, Maguire A, Duff D, Kelleher DP, Long A. Deoxycholic acid promotes development of gastroesophageal reflux disease and Barrett's oesophagus by modulating integrin-αv trafficking. J Cell Mol Med 2017;21:3612-25. [PMID: 28941013 DOI: 10.1111/jcmm.13271] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
3 Puchkov KV, Khabarova EV, Tishchenko ES. [Two-stage treatment of Barrett's esophagus]. Khirurgiia (Mosk) 2019;:18-24. [PMID: 31532162 DOI: 10.17116/hirurgia201909118] [Reference Citation Analysis]
4 Hvid-Jensen F, Funch-Jensen P, Drewes AM. Letter: proton pump inhibitors, GERD and oesophageal adenocarcinoma - authors' reply. Aliment Pharmacol Ther 2014;40:320. [PMID: 25040747 DOI: 10.1111/apt.12847] [Reference Citation Analysis]
5 Miyashita T, Shah FA, Harmon JW, Marti GP, Matsui D, Okamoto K, Makino I, Hayashi H, Oyama K, Nakagawara H, Tajima H, Fujita H, Takamura H, Murakami M, Ninomiya I, Kitagawa H, Fushida S, Fujimura T, Ohta T. Do proton pump inhibitors protect against cancer progression in GERD? Surg Today 2013;43:831-7. [DOI: 10.1007/s00595-012-0395-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
6 M'Harzi L, Chevallier JM, Certain A, Autret G, Levenson G, Louis D, Poghosyan T, Berger A, Rahmi G, Broudin C, Clément O, Douard R, Tavitian B, Bruzzi M. Long-Term Evaluation of Biliary Reflux on Esogastric Mucosae after One-Anastomosis Gastric Bypass and Esojejunostomy in Rats. Obes Surg 2020;30:2598-605. [PMID: 32130650 DOI: 10.1007/s11695-020-04521-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
7 Hu Q, Sun TT, Hong J, Fang JY, Xiong H, Meltzer SJ. Proton Pump Inhibitors Do Not Reduce the Risk of Esophageal Adenocarcinoma in Patients with Barrett's Esophagus: A Systematic Review and Meta-Analysis. PLoS One 2017;12:e0169691. [PMID: 28072858 DOI: 10.1371/journal.pone.0169691] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
8 Gronnier C, Bruyère E, Piessen G, Briez N, Bot J, Buob D, Leteurtre E, Van Seuningen I, Mariette C. Operatively induced chronic reflux in rats: a suitable model for studying esophageal carcinogenesis? Surgery. 2013;154:955-967. [PMID: 24084597 DOI: 10.1016/j.surg.2013.05.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
9 Alsalahi O, Dobrian AD. Proton Pump Inhibitors: The Culprit for Barrett's Esophagus? Front Oncol 2014;4:373. [PMID: 25621278 DOI: 10.3389/fonc.2014.00373] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
10 Aujeský R, Neoral C, Vrba R, Stašek M, Vomáčková K. The effect of laparoscopic fundoplication in therapy of Barrett's esophagus. Wideochir Inne Tech Maloinwazyjne 2014;9:213-8. [PMID: 25097689 DOI: 10.5114/wiitm.2014.41634] [Reference Citation Analysis]
11 Hoya Y, Taki T, Watanabe A, Nakayoshi T, Okamoto T, Mitsumori N, Yanaga K. Durable Flap-Valve Mitigation of Duodenogastric Reflux,  Remnant Gastritis and Dumping Syndrome Following Billroth I Reconstruction. J Gastrointest Surg 2016;20:772-5. [PMID: 26666548 DOI: 10.1007/s11605-015-3022-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Hvid-Jensen F, Pedersen L, Funch-Jensen P, Drewes AM. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients. Aliment Pharmacol Ther. 2014;39:984-991. [PMID: 24617286 DOI: 10.1111/apt.12693] [Cited by in Crossref: 71] [Cited by in F6Publishing: 54] [Article Influence: 8.9] [Reference Citation Analysis]
13 Wilson H, Mocanu V, Sun W, Dang J, Jogiat U, Kung J, Switzer N, Wong C, Karmali S. Fundoplication is superior to medical therapy for Barrett's esophagus disease regression and progression: a systematic review and meta-analysis. Surg Endosc 2021. [PMID: 34008109 DOI: 10.1007/s00464-021-08543-6] [Reference Citation Analysis]
14 Kapoor H, Lohani KR, Lee TH, Agrawal DK, Mittal SK. Animal Models of Barrett's Esophagus and Esophageal Adenocarcinoma-Past, Present, and Future. Clin Transl Sci 2015;8:841-7. [PMID: 26211420 DOI: 10.1111/cts.12304] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]